MAGE-TAB Version 1.1 Comment[MetaboBank accession] MTBKS258 Study Title Effects of treatment of differentiated thyroid cancer with radioactive iodine on the serum metabolome (FIA-MS) Study Description Differentiated thyroid cancer patients were treated with tyrogen (recombinant thyroid-stimulating hormone) on day -2 and 1.11 GBq of 131-I on day 0. Serum metabolomes before (day 0) and after (day 30) radioisotope therapy (Radioisotope therapy) was compared to discover biomarkers to evaluate treatment efficacy. Experimental Design compound treatment design Experimental Factor Name Administration of Tylogen and 131-I Experimental Factor Type Administration of Tylogen and 131-I Person Last Name Tatara Person First Name Yota Person Mid Initials Person Affiliation Graduate School of Medicine, Hirosaki University Person Roles submitter PubMed ID Publication DOI Protocol Name Sample collection Extraction Flow injection analysis Mass spectrometry Data processing Metabolite identification Protocol Type Sample collection Extraction Flow injection analysis Mass spectrometry Data processing Metabolite identification Protocol Description Serum samples were collected from patients and stored in a deep freezer. Ten µL urine was pipetted onto a filter containing isotopically-labeled internal standards on a 96-well-plate, dried under a nitrogen stream using a positive pressure manifold (Biotage AB), and 50 µL of 5% phenyl isothiocyanate (PITC) solution were added to each well to derivatize amino acids and biogenic amines. After 1h incubation time at room temperature, the plate was dried again. To extract the metabolites, 300 µL of 5 mM ammonium acetate in methanol were pipetted to each filter and incubated for 30 min. The extract was eluted into a new 96-well-plate using the positive pressure manifold. For FIA-MS/MS analyses, 10 µL extract was diluted with 490 µL solvent (Biocrates). Twenty microliters of the sample extract were used in the FIA in positive mode to capture acylcarnitines, glycerophospholipids, sphingolipids, and hexoses. All FIA injections were carried out using the Biocrates MS Running Solvent. Additional LC settings for LC-MS/MS are as follows: 0% B in 0.5 min; 0 to 95% B in 5 min; 95% B in 1 min; 95 to 0% B in 0.5 min; 0% B in 2.5 min at a flow rate of 0.5 ml/min. Quadrupole mass spectrometer settings for FIA mode are as follows: curtain gas, 30; ion spray voltage, 5500 V; temperature, 200°C; ion source gas 1, 40 psi; ion source gas 2, 50 psi; CAD gas, 6 psi; entrance potential, 10 V; collision cell exit potential, 15 V. Flow rate settings for FIA are as follows: 0.03 ml/min in 1.6 min; 0.03 to 0.2 ml/min in 0.8 min; 0.2 ml/min in 0.4 min; 0.2 to 0.03 ml/min in 0.2 min. Data acquisition: Analyst 1.6.3 (SCIEX) was used for data acquisition and processing. All metabolites were identified and quantified with isotopically-labeled internal standards and multiple reaction monitoring (MRM) as optimized and provided by Biocrates Inc. Protocol Parameters Post extraction;Derivatization FIA instrument Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer Protocol Hardware ExionLC AD (AB SCIEX) QTRAP6500+ (AB Sciex) Protocol Software Analyst 1.6.3 (SCIEX) MetIDQ carbon (Biocrates) Public Release Date 2025-06-25 Term Source Name Term Source File Term Source Version SDRF File MTBKS258.sdrf.txt Comment[Study type] targeted metabolite profiling Comment[Experiment type] flow injection analysis-mass spectrometry Comment[Submission type] FIA-MS Comment[BioProject] PRJDB20264 Comment[Related study] Comment[Contributor] Satoru Monzen (Department of Radiation Science, Graduate School of Health Sciences, Hirosaki University) Comment[Submission Date] 2025-02-10 Comment[Last Update Date] 2025-06-25